Analyst Price Targets — NOVT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 25, 2026 2:21 pm | Robert Mason | Robert W. Baird | $150.00 | $134.67 | TheFly | Novanta price target raised to $150 from $138 at Baird |
| March 3, 2025 12:13 pm | — | Robert W. Baird | $160.00 | $143.37 | TheFly | Novanta price target lowered to $160 from $169 at Baird |
| August 7, 2024 8:59 am | Robert Mason | Robert W. Baird | $175.00 | $174.36 | TheFly | Novanta price target raised to $175 from $170 at Baird |
Latest News for NOVT
Harvey Partners bought 304,000 shares of Novanta in the fourth quarter. The quarter-end position value increased by $36.17 million as a result.
CEO Matthijs Glastra sold 7,500 shares for a transaction value of ~$1.09 million on Feb. 10, 2026. This sale represented 6.29% of total holdings at the time.
Bradley Foster and Sargent Inc. CT increased its stake in Novanta Inc. (NASDAQ: NOVT) by 10.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 67,172 shares of the technology company's stock after purchasing an additional 6,128 shares during the period.
Novanta Inc. (NOVT) Q4 2025 Earnings Call Transcript
BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the fourth quarter and full year 2025. Financial Highlights Three Months Ended December 31, Year Ended December 31, (In millions, except per share amounts) 2025 2024 2025 2024 GAAP…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for NOVT.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.